<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200819048461N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-08</date_registration>
      <primary_sponsor>Pardis Specialized Wellness Institute</primary_sponsor>
      <public_title>The effect of home-based synchronous tele-exercise on balance, risk of fall, abnormality of posture, quality of life, level of physical activity and physical function in dialysis patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effect of home-based synchronous tele-exercise on balance, fall risk, postural abnormalities, quality of life, physical activity level, and functional status in hemodialysis patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/87274</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This study is a randomized controlled clinical trial with a parallel-group design and blinded outcome assessment. The unique feature of this trial is the comparison of home-based corrective exercise with synchronous online coach supervision in the intervention group versus the same exercise program without online supervision in the control group. Participants will be allocated using simple randomization with concealed allocation through opaque sealed envelopes, Randomization description: A simple random allocation sequence will be generated by an independent person using a random number generator software. Each allocation will be placed in a sequentially numbered, opaque, sealed envelope. After obtaining informed consent, the next envelope will be opened and the patient will be assigned to either the intervention or control group according to its content. Therefore, neither the researcher nor the patient is aware of the group assignment until the envelope is opened, Blinding description: The study is single-blind, and the collaborator who takes the functional tests from the patients and measures postural abnormalities with a flexible ruler and digital photography and completes the questionnaires will not be aware of the patient grouping.</study_design>
      <phase>N/A</phase>
      <hc_freetext>End-stage renal disease requiring hemodialysis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:Experimental group (with coach supervision): 12 weeks; 3 sessions/week exercise program at home on non-dialysis days with synchronous online supervision by coach via WhatsApp. The exercise program includes: general warm-up (5 minutes), corrective and strength exercises (15 minutes) and general cool-down (10 minutes), with the main exercise body starting at 15 minutes and gradually increasing by adding sets and repetitions to 30 minutes over three months. After each exercise, a 30 to 60 second rest is given to the patient. Intervention 2: Control group (without supervision): Participants receive the same home exercise program in a printed booklet but perform the exercises independently without synchronous online supervision. Both groups continue to receive usual medical care.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The results of the study group are made available

When:
After publication of the main results

To whom:
Only academics are allowed

Conditions:
If the data is used for the purpose of research in the field of variables and providing new solutions, it can be used by mentioning the source

Where to obtain:
Dr. Mohammad Ali Tabibi via email address m.tabibi@ut.ac.ir

How to obtain:
It will be answered within one month after receiving the email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nasrin Salimian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>71 Alley. Jey Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8156135414</zip>
        <telephone>0098 31 335252020</telephone>
        <email>statisrin@gmail.com</email>
        <affiliation>Pardis Specialized Wellness Institute</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mohammad Ali Tabibi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>71 alley. Jey street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174757536</zip>
        <telephone>0098 31 335252020</telephone>
        <email>m.tabibi@ut.ac.ir</email>
        <affiliation>Pardis Specialized Wellness Institute</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 40 and 60 years
At least three months of dialysis history
Receiving hemodialysis three times per week
No heart attack and stroke in the last three months
Ability to communicate with others
Doctor's permission for exercise</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unstable cardiac status (angina, congestive heart failure, severe arterial stenosis, uncontrolled arrhythmias, etc.)
Active infection or acute medical disease
Individuals with medically diagnosed unstable blood glucose levels (fluctuations between hypoglycemia and hyperglycemia)
Unable to exercise (lower limb amputation without prosthesis)
Severe musculoskeletal pain at rest or minimal activity
Shortness of breath at rest or with daily activities</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>End stage renal disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:Experimental group (with coach supervision): 12 weeks; 3 sessions/week exercise program at home on non-dialysis days with synchronous online supervision by coach via WhatsApp. The exercise program includes: general warm-up (5 minutes), corrective and strength exercises (15 minutes) and general cool-down (10 minutes), with the main exercise body starting at 15 minutes and gradually increasing by adding sets and repetitions to 30 minutes over three months. After each exercise, a 30 to 60 second rest is given to the patient.</i_keyword>
      <i_keyword>Control group (without supervision): Participants receive the same home exercise program in a printed booklet but perform the exercises independently without synchronous online supervision. Both groups continue to receive usual medical care.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Balance. Timepoint: Before intervention; after 12 weeks. Method of measurement: Berg Balance Scale (BBS), a 14-item performance-based instrument (e.g., sit-to-stand, unsupported standing, 360° turn, single-leg stance), each item scored 0 (unable) to 4 (independent); total score range 0–56, with lower scores indicating greater balance impairment and fall risk. Administered by a trained, blinded assessor in a clinical setting over approximately 15–20 minutes.</prim_outcome>
      <prim_outcome>Fall risk. Timepoint: Before intervention; after 12 weeks. Method of measurement: Tinetti Performance-Oriented Mobility Assessment (POMA), comprising a balance subscale (9 items, max 16 points) and a gait subscale (7 items, max 12 points); total score 0–28, with &lt;19 indicating high fall risk, 19–23 moderate risk, and ≥24 low risk. Administered via direct observation by an assessor blinded to group allocation.</prim_outcome>
      <prim_outcome>Forward head posture. Timepoint: Before intervention; after 12 weeks. Method of measurement: Craniovertebral angle (CVA) measured from a lateral-view digital photograph taken in natural standing posture; anatomical landmarks (spinous process of C7 and the tragus of the ear) are marked on the skin, and the angle between the horizontal line through the tragus and the line connecting the tragus to the C7 spinous process is calculated using AutoCAD (or equivalent angle-measurement software); a smaller angle indicates greater forward head posture severity (normal typically &gt;50°).</prim_outcome>
      <prim_outcome>Kyphosis. Timepoint: Before intervention; after 12 weeks. Method of measurement: Thoracic kyphosis angle measured using a Flexible Ruler; the ruler is molded over the T1–T12 spinous processes with the patient in natural standing posture and the spinal curve traced onto paper; the kyphosis angle is then calculated from the traced curve using the trigonometric formula Kyphosis Angle = arctan(4H/L), where H is the height of the curve and L is the baseline length; higher values indicate greater kyphotic curvature.</prim_outcome>
      <prim_outcome>Quality of life. Timepoint: Before intervention; after 12 weeks. Method of measurement: Kidney Disease Quality of Life – Short Form (KDQOL-36), comprising the generic SF-12 core plus kidney disease–specific components (symptoms/problems, effects of kidney disease on daily life, burden of kidney disease); each domain is scored 0–100, with higher scores indicating better quality of life. Self-administered by the patient after the dialysis session, with assistance from the research collaborator if needed.</prim_outcome>
      <prim_outcome>Physical activity level. Timepoint: Before intervention; after 12 weeks. Method of measurement: Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire, covering approximately 41 physical and social activities; participants report frequency and duration of each activity over the past week; output is expressed as estimated weekly caloric expenditure (kcal/kg/week) and weekly hours of moderate-to-vigorous activity, with higher scores indicating greater physical activity. Administered as an interviewer-based questionnaire by a blinded research collaborator.</prim_outcome>
      <prim_outcome>Functional status. Timepoint: Before intervention; after 12 weeks. Method of measurement: Six-Minute Walk Test (6MWT), conducted per the American Thoracic Society (ATS) standard protocol; the patient walks at maximal comfortable pace along a flat 30-meter corridor for 6 minutes, and the total distance covered (in meters) is recorded; a greater distance indicates better functional exercise capacity. Performed on a non-dialysis day by a blinded assessor.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hospitalization. Timepoint: During the study (5 months). Method of measurement: Number and cause of hospital admissions during the 5-month study period, recorded via a researcher-made checklist based on medical record review and patient self-report at each dialysis session.</sec_outcome>
      <sec_outcome>Mortality. Timepoint: During the study (5 months). Method of measurement: Recording of mortality cases and cause of death during the 5-month study period, via a researcher-made checklist based on review of the dialysis center's medical records.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Pardis Specialized Wellness Institute</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-22</approval_date>
        <contact_name>Ethics Committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences, Hezar Jerib Street, Isfahan, Iran Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
